Press Release

CIRCLE-seq, a Highly Sensitive in vitro Gene Editing Off-Target Assessment Technique, Exclusively Licensed by Beacon Genomics Published Online in Nature Methods

View printer-friendly PDF version

ALLSTON, MA, May 1, 2017 – CIRCLE-seq, developed in the laboratory of J. Keith Joung at Massachusetts General Hospital and exclusively licensed to Beacon Genomics, is a highly sensitive in vitro approach to screen for the off-target effects of gene editing. CIRCLE-seq utilizes highly sensitive next-generation sequencing-based methods and advanced informatics techniques to identify potential off-target site candidates. The CIRCLE-seq method was published today in an Advance Online Publication in Nature Methods as “CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas 9 nuclease off-targets.

Off-target effects can be a key concern for researchers and companies developing therapies and other products such as cell lines when using gene editing platforms including CRISPR-Cas9. Identifying the location and extent of off-target effects can help scientists to define and improve the safety of their therapeutic platforms.

CIRCLE-seq is the second exclusively licensed technology Beacon Genomics offers as a service for off-target specificity assessment. The first, GUIDE-seq, is a cell-based strategy for identifying potential off-target sites. Beacon Genomics also offers targeted sequencing for validation of off- target sites identified by the GUIDE-seq and CIRCLE-seq screening techniques.

About Beacon Genomics:

Beacon Genomics provides comprehensive services for off-target assessment for gene editing products via its exclusively licensed GUIDE-seq and CIRCLE-seq assays. These assays offer unbiased genome-wide approaches to better understand gene editing specificity. Scientific co- founders of Beacon Genomics include: J. Keith Joung (MGH), Martin Aryee (MGH) and Shengdar Tsai (St. Jude’s Children’s Hospital). Beacon’s customers include biotechnology, pharmaceutical and life science tools companies. Learn more at

Theresa Tribble
Business Development

Beacon Genomics

(p) 617-869-1284